Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
Micreos has been recognized by MedTech Outlook Magazine as the exclusive recipient of “Top 10 Dermatology Solution Companies - 2019,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the MedTech Outlook research and editorial team based on insights from an interview with Mr. Mark Offerhaus, CEO.
Mr. Mark Offerhaus, CEO![]()
Gladskin is the only healthy option in today’s market which is replete with corticosteroids and ineffective antibiotics for skincare and treatment
Company
Micreos
Management
Mr. Mark Offerhaus, CEO
Description
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos endolysin technology, for the first time only the unwanted bacteria can be killed - including antibiotic resistant strains - while preserving the beneficial bacteria, essential for our health. Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections
Sito Web:
mythras.it
Amministratore:
Roberto Livio Mastronardi, co-fondatore
Descrizione:
Mythras è un team di tecnici specializzati nell'assistenza tecnica su strumentazione IVD, esperti nell'aiutare i responsabili di laboratorio a garantire la precisione, l'accuratezza e la conformità dei loro strumenti. È la scelta ideale per numerosi clienti e distributori, al servizio delle loro complesse esigenze di assistenza tecnica e ricondizionamento della strumentazione IVD.
Citazione:
“Siamo certificati ISO 9001:2015 per l'assistenza tecnica e il ricondizionamento della strumentazione analitica IVD.”
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
